Awards and Grants

Charles Slemenda Award

The Charles Slemenda Award was established in 1999 and is awarded biennially in recognition of outstanding contributions to children’s bone research.


2022  Outi Makitie

2019  Nick Bishop

2017  Frank Rauch

2015  Zulf Mughal

2013  Maria Luisa Bianchi

2009  Michael Whyte

2007  Ailsa Goulding

2005  Jean-Philippe Bonjour

2002  John Pettifor

1999  Francis Glorieux

Charles Slemenda Award
Winner 2022

Outi Mäkitie

Helsinki, Finland

The Maria Luisa Bianchi Award was established in 2021 by ICCBH to honour the memory of Professor Maria-Luisa Bianchi for her role in in establishing and developing ICCBH and for her significant impact on the field of paediatric bone disease through her research and clinical work. The Award reflects on her commitment to the development of the field.

The goal of the award is to recognise the work of female researchers towards the beginning of their careers who have already made a significant contribution to the field of paediatric bone health and who are based in low- and middle-income countries.

The award will be made on the occasion of the International Conference on Children’s Bone Health, currently on a biennial basis.

The deadline for nominations for this award is 31 January 2024 (23:59 GMT) – more information about the eligibility and nomination process can be found HERE

Maria Luisa Bianchi Award
Winner 2022

Aashima Dabas

Aashima Dabas

New Delhi, India

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our Rare Disease division is focused on generating scientific and technological breakthroughs for people living with a rare disease via the discovery and development of integrated therapeutic solutions and novel indications of established medicines in rare and ultra-rare blood, endocrine and renal disorders. Novo Nordisk employs about 50,800 people in 80 countries out of which 3.300 within rare disease.

Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with a heritage of 70+ years, we apply cutting-edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa*, innovation and integrity.

*Harmony and loop among people.

Founded in 2007, Ascendis Pharma is applying its innovative TransCon™ technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by our core values of patients, science and passion, we use our TransCon technologies to fulfill our mission of developing new and potentially best-in-class therapies that address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States.

Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases driven by pathologic mineralization and intimal proliferation which impact the vasculature, soft tissue and skeleton. We are initially focused on developing an enzyme therapy to treat ENPP1 and ABCC6 Deficiencies, rare genetic diseases associated with significant morbidity, mortality, and unmet medical need.

BioMarin is a world leader in developing and commercializing innovative therapies for rare diseases driven by genetic causes. With a 20-year history, BioMarin remains steadfast to its original mission—to bring new treatments to market that will make a big impact on small patient populations. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options, and are usually ignored. Visit to learn more.

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.